EarningsThe company reported total revenues of $12.938bn, beating consensus of $12.571bn by 3%.
Financial GuidanceAZN raised financial guidance for FY24, guiding to mid-teens percentage increase for total revenue and core EPS.
Pipeline And Product GrowthManagement highlighted 2H Phase 3 trial readouts for Dato-DXd in TNBC, Imfinzi in 1L bladder cancer, Trucap in dPTEN HSPC, and Tezspire in CRwNP.